Universidade Federal de Ciências da Saúde de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90050-170, Brazil
NCT Number: NCT04580849
The aim of this study is to verify the feasibility of a telerehabilitation approach with dance in people with parkinson's disease.
Looking for future studies?
Notify Me45 year and older
All sexes
Interventional
Not applicable
Porto Alegre, Rio Grande do Sul, 90050-170, Brazil
This is a feasibility study that aims to investigate the safety and efficacy of dance classes via an online platform in people with and without Parkinson's Disease. The intervention will last 2 months and the classes will be conducted twice a week (60 minutes) using the Zoom platform. Evaluations will be performed before and after the intervention by means of the Zoom platform as well and will include questionnaires of quality of life, depression, anxiety, and activities of daily living.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
Time frame: 10 weeks
To assess the feasibility of the study design and procedures. The adherence rate will be calculated by the total number of patients who completed the full course of intervention divided by the total number of patients included at the beginning.
Time frame: 10 weeks
Semi structured interviews will involve gaining patients opinions on the strengths and weaknesses of the intervention
Time frame: 10 weeks
The researches will follow all patients during the intervention regarding safety (i.e. falls) and usability (i.e. internet connection)
Time frame: Change from Pre to Post treatment (10 weeks)
The PDQ-8 is a short-form version to assess quality of life in persons with Parkinson's disease. Each question is scored from 0-4 points and the scores are summed and given as a percentage score (0-100). The higher the score, the worse the patient's condition.
Time frame: Change from Pre to Post treatment (10 weeks)
The SF-36 measures health-related quality of life. This questionnaire has 36-item measure divided into 8 subscales - each subscale can be used independently. Each of the 8 summed scores is transformed into a scale from 0 (negative health) to 100 (positive health)
Time frame: Change from Pre to Post treatment (10 weeks)
The scale is used to identify depression and anxiety and presents 14 items. The total score is out of 42. The higher scores indicate greater levels of anxiety and depression.
Time frame: Change from Pre to Post treatment (10 weeks)
The Part I concerns about non-motor experiences of daily living (e.g. anxiety and depression). This scale has 13 questions and all items have 5 response options. Higher scores indicate greater impact of PD symptoms.
Time frame: Change from Pre to Post treatment (10 weeks)
Self-reported questionnaire measuring self-efficacy in performing activities without losing balance. The ABC Scale consists of 16 questions that require the patient to rate their confidence on a scale from 0% to 100%. The higher the percentage, the higher level of physical functioning.
Time frame: Change from Pre to Post treatment (10 weeks)
The test assess the functional mobility strength of lower extremity (measured by the time to complete the test). The higher the time to complete the test, the lower the performance.
Federal University of Health Science of Porto Alegre
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06133283
Basal Ganglia Diseases, Brain Diseases
San Antonio, Texas, United States
View Trial DetailsNCT05766813
Basal Ganglia Diseases, Brain Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07723027
Basal Ganglia Diseases, Brain Diseases
Shakargarh, Punjab Province, Pakistan
View Trial DetailsNCT07361250
Basal Ganglia Diseases, Brain Diseases
Wuhan, Hubei, China
View Trial Details